Avid Bioservices Inc (CDMO)

[north40000]

CELG/JUNO also play in your scenario—-and what entity or companies has Dr. Wolchok most often been an advisor to in CAR-T matters or otherwise? We do not know who he may have been asked to consult with on a private basis after AACR 2017 in April.

The answer to my last question may make no difference in a bidding battle should one develop. I suspect GILD would pay what is necessary to win that war for reasons already advanced here on this PPHM board, at least on an initial licensing or trial basis to investigate solid tumors as viable for the GILD/KITE CAR-T therapy from efficacy and safety standpoints.

First stop on that journey would be melanoma. Do not forget those other trials I have mentioned...”seamless trials” of one therapy for “multiple indications” mentioned by Dr. Janet Woodcock in her RAPS address; also mentioned or hinted at by Dr. Gottlieb in his earlier RAPS address this past summer.